Stem Cell Therapeutics closes unit offering

15 March 2013
Client work

On March 15, 2013, Stem Cell Therapeutics Corp. (TSXV: SSS), a life sciences company developing stem cell-related technologies, announced that it had closed its previously announced prospectus offering of units for the aggregate gross proceeds of $3,078,750. Euro Pacific Canada Inc. acted as the agent for the offering.

Gowlings was counsel to Euro Pacific Canada Inc. in this offering with a team that included Vanessa Grant, Anita Nador and Steven Cutler (corporate) and Gloria Geddes (tax), assisted by students-at-law Kelby Carter, Dan King and Matthew Literovich.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.
Related   Life Sciences, Mergers & Acquisitions, Tax

Related Insights & Resources

View all insights Related Insights & Resources
Articles
18 March 2019 Risks facing acquiring companies: liability to pay damages for EU competition law infringements committed by acquired businesses
Articles
02 August 2018 UK merger control - how (not) to respond to a request for information and other lessons
Client work
03 May 2018 Canadian Pharmacists Association invests in Pharmapod
Download or print PDF